Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in primary hypercholesterolemia patients not treated with a statin
2013-002659-14Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing Alirocumab with Placebo (2 arms). Primary endpoint: Percent change in LDL-C from baseline to Week 24. Started Sep 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2013-002659-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002659-14.